- Home
- KZIA vs PHGE Comparison
KZIA vs PHGE Comparison
Compare KZIA & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- PHGE
- Stock Information
- Founded
- KZIA 1994
- PHGE 2015
- Country
- KZIA Australia
- PHGE Israel
- Employees
- KZIA N/A
- PHGE N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- PHGE Health Care
- Exchange
- KZIA Nasdaq
- PHGE Nasdaq
- Market Cap
- KZIA 11.7M
- PHGE 13.0M
- IPO Year
- KZIA 1999
- PHGE N/A
- Fundamental
- Price
- KZIA $7.56
- PHGE $0.37
- Analyst Decision
- KZIA Strong Buy
- PHGE Strong Buy
- Analyst Count
- KZIA 3
- PHGE 1
- Target Price
- KZIA $16.00
- PHGE $15.00
- AVG Volume (30 Days)
- KZIA 72.8K
- PHGE 1.5M
- Earning Date
- KZIA 12-26-2025
- PHGE 11-12-2025
- Dividend Yield
- KZIA N/A
- PHGE N/A
- EPS Growth
- KZIA N/A
- PHGE N/A
- EPS
- KZIA N/A
- PHGE N/A
- Revenue
- KZIA $1,246,312.00
- PHGE N/A
- Revenue This Year
- KZIA N/A
- PHGE N/A
- Revenue Next Year
- KZIA N/A
- PHGE N/A
- P/E Ratio
- KZIA N/A
- PHGE N/A
- Revenue Growth
- KZIA N/A
- PHGE N/A
- 52 Week Low
- KZIA $2.86
- PHGE $0.34
- 52 Week High
- KZIA $34.40
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- KZIA 54.09
- PHGE 29.37
- Support Level
- KZIA $7.18
- PHGE $0.39
- Resistance Level
- KZIA $7.99
- PHGE $0.43
- Average True Range (ATR)
- KZIA 0.46
- PHGE 0.04
- MACD
- KZIA 0.03
- PHGE -0.02
- Stochastic Oscillator
- KZIA 72.19
- PHGE 2.67
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).